Jefferies raises Genmab price target as faith in cancer candidate grows

The US-based investment bank has updated its Genmab models after the company published its second quarterly report, raising its projections for cancer blockbuster Darzalex, among other things.

Photo: Joost Melis / Genmab / PR

Genmab’s share price target has been lifted to DKK 2,700 (USD 368.4) from DKK 2,350 (USD 320.6) by US-based investment bank Jefferies.

The bank has updated its models for the company following its second-quarter report, increasing the minimum estimated sales of blockbuster cancer drug Darzalex but maintaining the upper end of this projection, USD 15bn a year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs